Creative Planning’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$797K Buy
84,579
+17,377
+26% +$156K ﹤0.01% 2837
2026
Q1
$547K Buy
67,202
+4,473
+7% +$40.5K ﹤0.01% 2967
2025
Q4
$422K Sell
62,729
-36,373
-37% -$274K ﹤0.01% 2983
2025
Q3
$859K Sell
99,102
-6,768
-6% -$52.7K ﹤0.01% 2256
2025
Q2
$667K Buy
105,870
+72,213
+215% +$478K ﹤0.01% 2213
2025
Q1
$216K Sell
33,657
-6,065
-15% -$50.1K ﹤0.01% 3001
2024
Q4
$319K Buy
39,722
+7,240
+22% +$69.8K ﹤0.01% 2607
2024
Q3
$410K Buy
32,482
+8,339
+35% +$108K ﹤0.01% 2274
2024
Q2
$306K Buy
24,143
+2,692
+13% +$27.1K ﹤0.01% 2331
2024
Q1
$103K Buy
21,451
+2,291
+12% +$10.6K ﹤0.01% 2704
2023
Q4
$92K Buy
+19,160
New +$117K ﹤0.01% 2582
2023
Q3
Sell
-32,501
Closed -$241K 2992
2023
Q2
$241K Buy
32,501
+19,957
+159% +$157K ﹤0.01% 2075
2023
Q1
$86.9K Buy
12,544
+1,630
+15% +$15K ﹤0.01% 2280
2022
Q4
$112K Sell
10,914
-3,248
-23% -$57.3K ﹤0.01% 2130
2022
Q3
$258K Buy
14,162
+3,904
+38% +$169K ﹤0.01% 1744
2022
Q2
$528K Buy
10,258
+1,065
+12% +$55.2K ﹤0.01% 1284
2022
Q1
$677K Buy
9,193
+1,683
+22% +$150K ﹤0.01% 1176
2021
Q4
$1.07M Sell
7,510
-55
-0.7% -$9.45K ﹤0.01% 928
2021
Q3
$1.57M Buy
7,565
+41
+0.5% +$9.04K ﹤0.01% 761
2021
Q2
$1.6M Sell
7,524
-142,896
-95% -$26.2M ﹤0.01% 760
2021
Q1
$27.3M Sell
150,420
-3,881
-3% -$773K 0.05% 138
2020
Q4
$17.2M Buy
154,301
+26,385
+21% +$2.8M 0.04% 180
2020
Q3
$13.9M Buy
127,916
+34,608
+37% +$4.22M 0.04% 175
2020
Q2
$7.78M Buy
93,308
+15,936
+21% +$610K 0.02% 223
2020
Q1
$1.05M Buy
77,372
+38,232
+98% +$324K ﹤0.01% 627
2019
Q4
$156K Sell
39,140
-53,204
-58% -$231K ﹤0.01% 1688
2019
Q3
$464K Buy
92,344
+13,101
+17% +$71.7K ﹤0.01% 1111
2019
Q2
$464K Buy
79,243
+53,577
+209% +$422K ﹤0.01% 1122
2019
Q1
$283K Buy
25,666
+15,860
+162% +$501K ﹤0.01% 1360
2018
Q4
$361K Sell
9,806
-1,659
-14% -$64.3K ﹤0.01% 1129
2018
Q3
$431K Sell
11,465
-2,320
-17% -$65.3K ﹤0.01% 1178
2018
Q2
$369K Sell
13,785
-27
-0.2% -$913 ﹤0.01% 1250
2018
Q1
$580K Buy
13,812
+3,622
+36% +$146K ﹤0.01% 1009
2017
Q4
$253K Sell
10,190
-9,652
-49% -$235K ﹤0.01% 1448
2017
Q3
$452K Sell
19,842
-3,768
-16% -$84.4K ﹤0.01% 1105
2017
Q2
$543K Buy
23,610
+7,407
+46% +$145K ﹤0.01% 972
2017
Q1
$415K Sell
16,203
-14,133
-47% -$389K ﹤0.01% 1096
2016
Q4
$764K Buy
30,336
+17,477
+136% +$510K ﹤0.01% 735
2016
Q3
$535K Sell
12,859
-10,704
-45% -$1.38M ﹤0.01% 856
2016
Q2
$3.43M Sell
23,563
-12
-0.1% -$1.38K 0.02% 226
2016
Q1
$2.43M Buy
23,575
+2,312
+11% +$248K 0.02% 278
2015
Q4
$3.57M Buy
21,263
+290
+1% +$44.6K 0.03% 213
2015
Q3
$2.97M Buy
20,973
+20,400
+3,560% +$4.57M 0.03% 221
2015
Q2
$128K Sell
573
-2
-0.3% -$352 ﹤0.01% 958
2015
Q1
$95K Buy
575
+100
+21% +$16.2K ﹤0.01% 1603
2014
Q4
$56K Buy
475
+150
+46% +$15.7K ﹤0.01% 1935
2014
Q3
$27K Hold
325
﹤0.01% 2324
2014
Q2
$30K Buy
325
+93
+40% +$8.17K ﹤0.01% 2227
2014
Q1
$21K Buy
232
+10
+5% +$1.12K ﹤0.01% 2339
2013
Q4
$23K Buy
222
+45
+25% +$3.18K ﹤0.01% 2105
2013
Q3
$11K Hold
177
﹤0.01% 2411
2013
Q2
$7K Buy
+177
New +$7.67K ﹤0.01% 2416

Other funds holding NVAX

Creative Planning's NVAX Position: Q2 2026 in Review

Creative Planning increased its Novavax (NVAX) stake by 26% in Q2 2026, buying an estimated $156K and bringing the position to 84,579 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

Creative Planning first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $27.3M in Q1 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Creative Planning held 84,579 shares of Novavax worth $797K as of Q2 2026.
  • Creative Planning bought 17,377 Novavax shares in Q2 2026, an estimated $156K.
  • Novavax made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2837 holding.
  • Creative Planning first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Novavax position peaked at $27.3M in Q1 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.